Gracell Biotechnologies Inc. (GRCL) Social Stream
GRACELL BIOTECHNOLOGIES INC (GRCL) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering GRCL.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-15 | 4 | $40 | $31 | $34.75 | $10.05 | 245.77% |
| 2021-11-18 | 1 | $40 | $27 | $33.5 | $10.05 | 233.33% |
| 2022-03-15 | 2 | $25 | $21 | $23 | $10.05 | 128.86% |
| 2022-05-16 | 3 | $25 | $18 | $21.333 | $10.05 | 112.27% |
| 2022-05-27 | 3 | $21 | $10 | $16.333 | $10.05 | 62.52% |
| 2022-08-15 | 5 | $21 | $10 | $17.25 | $10.05 | 71.64% |
| 2022-08-18 | 5 | $21 | $7 | $15.2 | $10.05 | 51.24% |
| 2022-11-15 | 6 | $21 | $7 | $14.666 | $10.05 | 45.93% |
| 2022-12-12 | 7 | $21 | $6 | $13.428 | $10.05 | 33.61% |
| 2023-03-13 | 7 | $21 | $7 | $14.285 | $10.05 | 42.14% |
| 2023-03-14 | 7 | $20 | $7 | $11.666 | $10.05 | 16.08% |
| 2023-05-22 | 6 | $20 | $7 | $11.666 | $10.05 | 16.08% |
| 2023-08-14 | 7 | $20 | $7 | $13 | $10.05 | 29.35% |
| 2023-08-29 | 7 | $20 | $7 | $12.714 | $10.05 | 26.51% |
| 2023-11-03 | 8 | $20 | $7 | $12.5 | $10.05 | 24.38% |
| 2023-11-13 | 8 | $20 | $7 | $11.428 | $10.05 | 13.71% |
| 2023-11-15 | 8 | $20 | $7 | $11.714 | $10.05 | 16.56% |
| 2023-12-26 | 9 | $20 | $7 | $11.285 | $10.05 | 12.29% |
| 2023-12-27 | 9 | $20 | $10 | $11.928 | $10.05 | 18.69% |
The Trend in the Analyst Price Target
Over the past 50 weeks, GRCL's average price target has gone down $2.36.
GRCL reports an average of 326.84% for its upside potential over the past 50 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-03-14 | 7 | 20 | 7 | 11.666 | 1.82 | 540.99% |
| 2023-08-14 | 7 | 20 | 7 | 12.857 | 3.89 | 230.51% |
| 2023-08-14 | 7 | 20 | 7 | 13.000 | 3.89 | 234.19% |
| 2023-08-29 | 7 | 20 | 7 | 12.714 | 3.57 | 256.13% |
| 2023-11-03 | 8 | 20 | 7 | 12.500 | 4.24 | 194.81% |
GRCL Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.11 | 4 | 0 | 5 | 0 | 0 | 9 |
The Trend in the Broker Recommendations
GRCL's average broker recommendation rating worsened by 0.67 over the prior 48 weeks.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In terms of how GRACELL BIOTECHNOLOGIES INC fares relative to all US stocks, note that its variance in analysts' estimates is lower than -1885.11% of that group.
- In the context of all US stocks, GRACELL BIOTECHNOLOGIES INC's average analyst price target is greater than 571.4% of them.
- GRACELL BIOTECHNOLOGIES INC's number of analysts covering the stock is greater than 1653.45% of stocks in the small market cap category.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, GRACELL BIOTECHNOLOGIES INC's upside potential (average analyst target price relative to current price) is higher than 999.79% of them.
In the Pharmaceutical Products industry, EFTR, BOLT, and TERN are the three stocks most similar to GRACELL BIOTECHNOLOGIES INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is GRCL a Buy, Hold or Sell? See the POWR Ratings now!